Replies to post #31895 on Marker Therapeutics Inc (MRKR)

[microcapbiotech]

OK, "No. This was one of the first people dosed in the safety lead in."

SO, unless I'm crazy, results in the future, using the "9 day 4 X better" should produce MUCH BETTER outcomes.

"Yes. It does seem that way."

Ok, like you and Hanscott said, makes sense, seems reasonable, it's just that the timing and share price suck, but may be better in the long run (if we can make it there).

"The patients they are treating have already failed multiple lines of treatment. I think in the PI it was 4-10 prior lines of therapy failed.
The active patients are running out of options and nothing is working.
The chance of curing them is small."

Then God I hope the FDA isn't expecting miracles, if it helps some people, then it helps some people, that beats the hell out of NOTHING. WTF?

P.S. Thanks again for your responses.

[GoIrish1776]

IMO, they changed the trial design, delaying the trial, crushing the SP and risking terrible dilution for one of three reasons:
1) they are naïve (5%)
2) they believe they have the goods in the active arm w the current process and believe the SP will take off with the release of data “Q1/Q2” (5%)
3) they knew the active data is bad based on the 6 lead in and currently dosed patients and they wanted to get out ahead of it with some kind of story rather than release bad data and getting totally crushed later (90%)

Said differently, we’re getting what we deserve in a way. The trial didn’t work. They are finding a way to salvage something but we’re paying or are about to pay a very bad price.

I had the thought not long ago that the prudent thing to do was raise $20m or so when the SP was under $1. I would have cursed them but it would have been prudent. There is no bottom now. Maybe some level of cash.